Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 112053

1.

Genital melanoma: are we adequately screening our patients?

Zikry J, Chapman LW, Korta DZ, Smith J.

Dermatol Online J. 2017 Mar 15;23(3). pii: 13030/qt7zk476vn.

PMID:
28329513
2.

Challenges to smartphone applications for melanoma detection.

Wang JV, Chapman LW, Keller M.

Dermatol Online J. 2017 Feb 15;23(2). pii: 13030/qt4c37w7g2.

PMID:
28329502
3.

Mohs micrographic surgery and secondary intention healing of a plantar melanoma in-situ.

Schoenfeld J, Wirth P, Helm T.

Dermatol Online J. 2017 Feb 15;23(2). pii: 13030/qt7d02z4f7.

PMID:
28329499
4.
5.

Brugada syndrome induced by BRAF and MEK inhibitors in a melanoma patient.

Nardin C, Colas M, Badoz M, Roche-Kubler B, Meneveau N, Puzenat E, Aubin F.

Eur Heart J. 2017 Mar 18. doi: 10.1093/eurheartj/ehx133. [Epub ahead of print] No abstract available.

PMID:
28329154
6.

Chronic Resveratrol Treatment Inhibits MRC5 Fibroblast SASP-Related Protumoral Effects on Melanoma Cells.

Menicacci B, Laurenzana A, Chillà A, Margheri F, Peppicelli S, Tanganelli E, Fibbi G, Giovannelli L, Del Rosso M, Mocali A.

J Gerontol A Biol Sci Med Sci. 2017 Jan 20. doi: 10.1093/gerona/glw336. [Epub ahead of print]

PMID:
28329136
7.

Long-Term Outcomes of Melanoma In Situ Treated With Topical 5% Imiquimod Cream: A Retrospective Review.

Park AJ, Paul J, Chapman MS, Samie FH.

Dermatol Surg. 2017 Mar 21. doi: 10.1097/DSS.0000000000001115. [Epub ahead of print]

PMID:
28328708
8.

MicroRNA-488-3p sensitizes malignant melanoma cells to cisplatin by targeting PRKDC.

Li N, Ma Y, Ma L, Guan Y, Ma L, Yang D.

Cell Biol Int. 2017 Mar 22. doi: 10.1002/cbin.10765. [Epub ahead of print]

PMID:
28328082
9.

Efficacy and Safety of Nilotinib in Patients With KIT-Mutated Metastatic or Inoperable Melanoma: Final Results From the Global, Single-Arm, Phase II TEAM Trial.

Guo J, Carvajal RD, Dummer R, Hauschild A, Daud A, Bastian BC, Markovic SN, Queirolo P, Arance A, Berking C, Camargo V, Herchenhorn D, Petrella TM, Schadendorf D, Sharfman W, Testori A, Novick S, Hertle S, Nourry C, Chen Q, Hodi FS.

Ann Oncol. 2017 Mar 6. doi: 10.1093/annonc/mdx079. [Epub ahead of print]

PMID:
28327988
10.

Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.

Lee JH, Long GV, Boyd S, Lo S, Menzies AM, Tembe V, Guminski A, Jakrot V, Scolyer RA, Mann GJ, Kefford RF, Carlino MS, Rizos H.

Ann Oncol. 2017 Jan 24. doi: 10.1093/annonc/mdx026. [Epub ahead of print]

PMID:
28327969
11.

GENOTYPE ASSOCIATION GSTM1 NULL AND GASTRIC CANCER: EVIDENCE-BASED META-ANALYSIS.

Ribeiro RX, Nascimento CI, Silva AM.

Arq Gastroenterol. 2017 Mar 16:0. doi: 10.1590/S0004-2803.201700000-14. [Epub ahead of print]

PMID:
28327825
12.

FMNL formins boost lamellipodial force generation.

Kage F, Winterhoff M, Dimchev V, Mueller J, Thalheim T, Freise A, Brühmann S, Kollasser J, Block J, Dimchev G, Geyer M, Schnittler HJ, Brakebusch C, Stradal TE, Carlier MF, Sixt M, Käs J, Faix J, Rottner K.

Nat Commun. 2017 Mar 22;8:14832. doi: 10.1038/ncomms14832.

PMID:
28327544
13.

Primary hepatic angiomyolipoma: immunohistochemistry and electron microscopic observations: a case report.

Kubo H, Yamazaki H, Okada T, Takahashi Y, Nishi Y, Yokomori H.

J Med Case Rep. 2017 Mar 22;11(1):76. doi: 10.1186/s13256-017-1235-1.

PMID:
28327196
14.

Psychiatric comorbidity and suicidal ideation in psoriasis, melanoma and allergic disorders.

Pompili M, Innamorati M, Forte A, Erbuto D, Lamis DA, Narcisi A, Rea C, Orsini D, D'Arino A, Arcese A, Bellini S, Trovarelli S, Serafini G, Amore M, Costanzo A, Girardi P.

Int J Psychiatry Clin Pract. 2017 Mar 22:1-6. doi: 10.1080/13651501.2017.1301482. [Epub ahead of print]

PMID:
28326880
15.

Checkpoint inhibitors in the treatment of brain metastases of non-small-cell lung cancer and melanoma.

Kourie HR, Kanaan H, Awada G, Awada AH.

Future Oncol. 2017 Feb 28. doi: 10.2217/fon-2016-0494. [Epub ahead of print]

PMID:
28326837
16.

Current status of clinical trials assessing oncolytic virus therapy for urological cancers.

Taguchi S, Fukuhara H, Homma Y, Todo T.

Int J Urol. 2017 Mar 21. doi: 10.1111/iju.13325. [Epub ahead of print] Review.

PMID:
28326624
17.

Targeted Treatment of Brain Metastases.

Shonka N, Venur VA, Ahluwalia MS.

Curr Neurol Neurosci Rep. 2017 Apr;17(4):37. doi: 10.1007/s11910-017-0741-2. Review.

PMID:
28326470
18.

Erratum to: Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.

Hermel DJ, Ott PA.

Cancer Metastasis Rev. 2017 Mar 22. doi: 10.1007/s10555-017-9665-1. [Epub ahead of print] No abstract available.

PMID:
28326450
19.

p75 Neurotrophin Receptor in the Skin: Beyond Its Neurotrophic Function.

Pincelli C.

Front Med (Lausanne). 2017 Mar 7;4:22. doi: 10.3389/fmed.2017.00022. Review.

PMID:
28326307
20.

Determining the epidemiologic, outcome, and prognostic factors of oral malignant melanoma by using the Surveillance, Epidemiology, and End Results database.

Lee RJ, Lee SA, Lin T, Lee KK, Christensen RE.

J Am Dent Assoc. 2017 Mar 18. pii: S0002-8177(17)30076-4. doi: 10.1016/j.adaj.2017.01.019. [Epub ahead of print]

PMID:
28325493

Supplemental Content

Loading ...
Support Center